

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March 2021**

Commission File Number: **000-30314**

**PORTAGE BIOTECH INC.**

(Translation of registrant's name into English)

**6 Adelaide St. East, Suite 300  
Toronto, Ontario, Canada M5C 1H6**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): \_\_\_\_\_

---

<u>Exhibit</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">News Release dated March 2, 2021</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Portage Biotech Inc.**  
(Registrant)

Date: March 2, 2021

By /s/ Ian Walters  
Ian Walters MD  
Chief Executive Officer



**PORTAGE BIOTECH INC.**

**NEWS RELEASE**

**PORTAGE ANNOUNCES FILING OF THIRD QUARTER FINANCIAL STATEMENTS**

**Toronto, ON** - (March 2, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immune-oncology company accelerating research and development to overcome immune resistance, today announced the filing of its interim financial statements and related management's analysis and discussion for the period ended December 31, 2020 (the third quarterly filings.) These documents are available from [SEDAR](#), the [SEC](#), and the company's website at [www.portagebiotech.com](http://www.portagebiotech.com).

Highlights for the period and recent weeks are:

- February 25, 2021 - Company's ordinary shares commence trading on NASDAQ under the symbol PRTG
- February 24, 2021- Company [files Form F-3](#) for a \$200 million shelf registration statement-
- February 11, 2021 - Company issues [Research & Development update](#) and 2021 plans to advance three clinical trial assets in its pipeline

"Filing the shelf registration statement is an important step as we look to drive value for our stakeholders," said Allan Shaw, chief financial officer of Portage Biotech. This is part of our plan to obtain the capital needed to effectively accelerate and execute our developmental activities and continue to advance our portfolio of platforms with unique mechanisms of action for the immune-oncology market from discovery to the clinic."

To learn more about Portage, please visit [www.portagebiotech.com](http://www.portagebiotech.com)

**About Portage Biotech Inc.**

Portage is a clinical stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company's access to next-generation technologies coupled with a deep understanding of biological mechanisms enables identification of the most promising clinical therapies and product development strategies that accelerate the translation from the bench to human proof of concept. Portage's portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months.

---

## ***Forward-Looking Statements***

This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

### **FOR MORE INFORMATION, PLEASE CONTACT:**

Contact: [Media@portagebiotech.com](mailto:Media@portagebiotech.com)  
[www.portagebiotech.com](http://www.portagebiotech.com)

#### **Investor Relations**

Chuck Padala [chuck@lifesciadvisors.com](mailto:chuck@lifesciadvisors.com)

#### **Media Relations**

Kate Caruso-Sharpe [kcaruso-sharpe@lifescicomms.com](mailto:kcaruso-sharpe@lifescicomms.com)